132
R.R. Parvatkar et al. / Phytochemistry 70 (2009) 128–132
Table 2
We are grateful to Dr. (Mrs.) Solimabi Wahidulla, senior scientist,
National Institute of Oceanography and Prof. S.K. Paknikar, Retd.
Prof., Department of Chemistry, Goa University for critically
reviewing the manuscript. We also thank Dr. P.D. Mishra, Dr.
Asha Almeida and Dr. Pari Koteppa, Nicholas Piramal Research
Center, Mumbai for carrying out biological screening and
500 MHz NMR facility.
1H and 13C NMR spectroscopic data of compounds 2 and 3 (300 MHz, CDCl3+ 2drops
CD3OD).
Carbon
No.
Aspernolide B (2)
dC, mult.
dH, mult., J
(Hz)
Aspernolide C (3)
dC, mult.
dH, mult., J
(Hz)
1
2
3
4
169.2 s
137.9 s
128.3 s
85.6 s
169.3 s
137.9 s
128.2 s
85.7 s
5
6
10
20(60)
30(50)
40
100
200
300
400
500
600
170.1 s
38.3 t
170.1 s
38.4 t
121.8 s
References
3.46, s
3.43, s
121.6 s
129.1 d
115.6 d
157.5 s
128.1 s
131.7 d
124.0 s
153.2 s
114.6 d
128.6 d
Alberts, A.W., Chen, J., Kuron, G., Hunt, V., Huff, J., Hoffman, C., Rothrock, J., Lopez,
M., Joshua, H., Harris, E., Patchett, A., Monaghan, R., Currie, S., Stapley, E., Albers-
Schonberg, G., Hensens, O., Hirshfield, J., Hoogsteen, K., Liesch, J., Springer, J.,
1980. Mevinolin: a highly potent competitive inhibitor of hydroxymethyl-
glutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl.
Acad. Sci. USA 77, 3957–3961.
Bachmann, M., Luethy, J., Schlatter, C., 1979. Toxicity and mutagenicity of molds of
the Aspergillus glaucus group. Identification of physcion and three related
anthraquinones as main toxic constituents from Aspergillus chevalieri. J. Agric.
Food Chem. 27 (6), 1342–1347.
Brachmann, A.O., Forst, S., Furgani, G.M., Fodor, A., Bode, H.B., 2006. Xenofuranones
A and B: phenylpyruvate dimers from Xenorhabdus szentirmaii. J. Natl. Prod. 69,
1830–1832.
Brana, M.F., Garcia, M.L., Lopez, B., Pascual-Teresa, B., Ramos, A., Pozuelo, J.M.,
Dominguez, M.T., 2004. Synthesis and biological evaluation of analogues of
butyrolactone I and molecular model of its interaction with CDK2. Org. Biomol.
Chem. 2, 1864–1871.
7.55, d (8.7) 129.2 d
6.87, d (8.7) 115.0 d
157.5 s
128.1 s
6.41, d (1.8) 131.8 d
124.0 s
7.54, d (8.7)
6.85, d (8.7)
6.40, d (1.8)
153.4 s
6.52, d (8.7) 114.4 d
6.49, d (8.1)
6.54, dd
(8.1, 1.8)
2.35, m
6.55, dd
(8.7, 1.8)
2.37, m
128.9 d
700
24.2 t
43.2 t
70.8 s
28.4 q
28.5 q
–
23.2 t
40.0 t
75.4 s
24.0 q
24.4 q
49.0 q
53.3 q
800
1.53, t (7.8)
1.54, t (7.8)
900
1000
1100
1200
5-OMe
1.20, s
1.19, s
1.12, s
1.12, s
3.15, s
3.74, s
Bugni, T.S., Ireland, C.M., 2003. Marine-derived fungi: a chemically and biologically
diverse group of microorganisms. Natl. Prod. Rep. 21, 143–163.
Dunn, A.W., Ian, D.E., Johnstone, A.W., 1975. Terrein and other metabolites of Phoma
species. Phytochemistry 14, 2081–2082.
53.5 q
3.76, s
Faulkner, D.J., 2000. Marine natural products. Natl. Prod. Rep. 17, 7–55.
Fischer, P.M., Lane, D.P., 2000. Inhibitors of cyclin-dependent kinases as anti-cancer
therapeutics. Current Med. Chem. 7, 1213–1245.
Kim, W., Cho, K., Lee, C., Yoo, I.D., 2002. Terreulactone A, a novel meroterpenoid
with anti-acetylcholinesterase activity from Aspergillus terreus. Tetrahedron
Lett. 43 (17), 3197–3198.
Kiriyama, N., Nitta, K., Sakaguchi, Y., Tagushi, Y., Yamamoto, Y., 1977. Studies on the
metabolic products of Aspergillus terreus. III. Metabolites of the strain IFO 8835.
Chem. Pharm. Bull. (Tokyo) 25 (10), 2593–2601.
4.3.3. Butyrolactone I (3)
White powder;
½
a 2D8:8
ꢂ
þ 84:32ꢃ (c 0.617, MeOH); and
½
a 2D8:8
ꢂ
þ 87:56ꢃ (c 0.617, CHCl3); 1H NMR and 13C NMR data were
in agreement with the literature (Rao et al., 2000); HRESITOFMS:
[M + H]+ m/z 424.1516 (calcd. 424.1522 for C24H25O7).
Macedo Jr., C.F., Porto, A.L.M., Marsaioli, A.J., 2004. Terreinol – a novel metabolite
from Aspergillus terreus: structure and 13C labeling. Tetrahedron Lett. 45 (1), 53–
55.
Morishima, H., Fujita, K., Nakano, M., Atsumi, S., Ookubo, M., Kitagawa, M.,
Matsumoto, H., Okunyama, A., Okabe, T., Suda, H., Nishimura, S., 1994. Jpn.
Kokai Tokkyo Koho.
Nishio, K., Ishida, A., Arioka, H., Kurokawa, H., Fukuoka, K., Nomoto, T., Fukumoto, H.,
Yokote, H., Saijo, N., 1996. Antitumor effects of butyrolactone I, a selective cdc2
kinase inhibitor, on human lung cancer cell lines. Anticancer Res. 16, 3387–
3395.
Nitta, K., Fujita, N., Yoshimura, T., Arai, K., Yamamoto, U., 1983. Metabolic products
of Aspergillus terreus. IX. Biosynthesis of butyrolactone derivatives isolated from
strain IFO 8835 and 4100. Chem. Pharm. Bull. (Tokyo) 31 (5), 1528–
1533.
Niu, X., Dahse, H., Menzel, K., Lozach, O., Walther, G., Meijer, L., Grabley, S., Sattler, I.,
2008. Butyrolactone I derivatives from Aspergillus terreus carrying an unusual
sulfate moiety. J. Natl. Prod. 71, 689–692.
Rao, K.V., Sadhukhan, A.K., Veerender, M., Mohan, E.V.S., Dhanvantri, S.D.,
Sitaramkumar, S., Babu, M.J., Vyas, K., Reddy, O.G., 2000. Butyrolactones from
Aspergillus terreus. Chem. Pharm. Bull. (Tokyo) 48 (4), 559–562.
Saleem, M., Ali, M.S., Hussain, S., Jabbar, A., Ashraf, M., Lee, Y.S., 2007. Marine natural
products of fungal origin. Natl. Prod. Rep. 24, 1142–1152.
4.3.4. Aspernolide C (8)
Light brown syrup; for 1H and 13C NMR spectroscopic data see
Table 2; HRESITOFMS: [M + H]+ m/z 457.1851 (calcd. 457.1862
for C25H29O8) and [M + Na]+ m/z 479.1669 (calcd. 479.1682 for
C25H28O8Na).
4.4. Conversion of butyrolactone I (3) to aspernolides A (1), B (2) and C
(8)
Butyrolactone I (3), (76.9 mg) was dissolved in MeOH (10 ml)
containing conc. HCl (0.2 ml). The mixture was stirred at rt approx-
imately for 2 h. or until complete conversion of 3 as indicated by
TLC. The solvent was removed under vacuum and the resulting res-
idue was separated on a flash Si-gel column using gradient elution
of MeOH–CHCl3 (0:100–20:80) to yield in order of increasing
polarity 1 (58.6 mg, 75%), 8 (8.8 mg, 10.4%) and 2 (6.9 mg, 8.3%).
Schimmel, T.G., Parsons, S.J., 1999. High purity, high yield procedure for
butyrolactone I production from Aspergillus terreus. Biotechnol. Techniques 13,
379–384.
Acknowledgement
Suzuki, M., Hosaka, Y., Matsushima, H., Goto, T., Kitamura, T., Kawabe, K., 1999.
Butyrolactone I induces cyclin B1 and causes G2/M arrest and skipping of
mitosis in human prostate cell lines. Cancer Lett. 138, 121–130.
We sincerely acknowledge the Ministry of Earth Sciences
(MoES), New Delhi for funding the project. Authors RRP and
CDs are grateful to University Grant Commission (UGC), New
Delhi and MoES, for research fellowship and project assistantship.